Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology 2022, 164: 61-71. PMID: 36228734, DOI: 10.1053/j.gastro.2022.09.041.Peer-Reviewed Original ResearchConceptsMaintenance of healingProton pump inhibitorsErosive esophagitisSecondary analysisD esophagitisPrimary analysisEnd pointPotassium-competitive acid blocker vonoprazanHeartburn-free daysSevere erosive esophagitisMainstay of treatmentPrimary end pointSecondary end pointsPotent acid inhibitionPPI lansoprazolePump inhibitorsEsophagitisNoninferiority comparisonVonoprazanWeek 2Healing phaseAbstractTextPatientsLansoprazoleSuperiority analysisPharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, Howden CW. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. The American Journal Of Gastroenterology 2022, 117: 1158-1161. PMID: 35294415, DOI: 10.14309/ajg.0000000000001735.Peer-Reviewed Original ResearchConceptsPotassium-competitive acid blocker vonoprazanProton pump inhibitor lansoprazolePotassium-competitive acid blockerUS subjectsDays of washoutFirst doseIntragastric acidityAcid blockerDay 1VonoprazanDay 7Healthy adultsLansoprazolePotent inhibition